	Application No.	Applicant(s)
Notice of Allowability	10/658,904	KAPELLER-LIBERMANN, ROSANA
	Examiner	Art Unit
	Maryam Monshipouri	1656
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to		
2. The allowed claim(s) is/are <u>5,6,12,13,15,16,21,23-28 and 35</u> .		
3. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) All b) Some* c) None of the:  1. Certified copies of the priority documents have been received.  2. Certified copies of the priority documents have been received in Application No  3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.  THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS ( as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review ( PTO-948) attached		
1)  hereto or 2)  to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
		·
Attachment(s)	E D Notice of Informal E	Potent Application
1. Notice of References Cited (PTO-892)	<ol> <li>5. ☐ Notice of Informal F</li> <li>6. ☒ Interview Summary</li> </ol>	
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	Paper No./Mail Da	r No./Mail Date <u>filed 3/14/07</u> .
<ul> <li>3.</li></ul>	7. ⊠ Examiner's Amendment/Comment	
	8. 🛛 Examiner's Stateme	ent of Reasons for Allowance
	9.  Other	

Control of the second s

Serial Number: 10/658,904

Art Unit 1656

An Examiner's Amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be

Authorization for this Examiner's Amendment was given in a telephone interview with Ms. Tracy M., Sioussat, on 3/14/07.

**Examiner's Amendment to the Claims** 

Cancel claims 29-34.

**Examiner's Amendments to the Specification** 

submitted no later than the payment of the issue fee.

The following is an Examiner's Statement of Reasons for Allowance:

Claims 5-6, 12-13, 15-16, 21, 23-28, 35 are directed to an isolated 14171 kinase of specific amino acid composition, specifically claimed homologs thereof and methods of screening for compounds that modulate said products.

Claimed amino acid sequence of said kinase is free of prior art. Further the prior art does not teach or suggest preparing such specifically claimed amino acid sequence. Hence, said sequence is also non-obvious. Since said amino acid sequence is both novel and non-obvious, specifically claimed homologs thereof, and methods of use of said polypeptides as claimed, are also novel and non-obvious.

Claims 5-6, 12-13, 15-16, 21, 23-28 and 35 are allowed.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably

Serial Number: 10/658,904

Art Unit 1656

accompany the issue fee. Such submissions should be clearly labeled "Comments on

Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Maryam Monshipouri whose telephone number is (571)

272-0932. The examiner can normally be reached on 7:00 a.m to 5:30 p.m...

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Kathleene Kerr Bragdon can be reached on (571) 272-0931. The fax phone

number for the organization where this application or proceeding is assigned is 571-

273-8300.

Information regarding the status of an application may be obtained from the

Patent Application Information Retrieval (PAIR) system. Status information for

published applications may be obtained from either Private PAIR or Public PAIR.

Status information for unpublished applications is available through Private PAIR only.

For more information about the PAIR system, see http://pair-direct.uspto.gov. Should

you have guestions on access to the Private PAIR system, contact the Electronic

Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a

USPTO Customer Service Representative or access to the automated information

system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Maryam Monshipouri Ph.D.

Primary Examiner

3